Matinas BioPharma's total assets for Q3 2024 were $20.58M, a decrease of -15.55% from the previous quarter. MTNB total liabilities were $4.80M for the fiscal quarter, a -8.82% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.